Corbus Pharmaceuticals Holdings, Inc. (CRBP) Stock Research
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.
Latest price: 3.915 · Sector: Healthcare
Recent Insider Transactions
| Insider | Type | Date | Value |
|---|---|---|---|
| Cormorant Asset Management, LP | sell | 2026-10-29 | 1742755 |
| Ben Yong | sell | 2026-09-14 | 15683 |
| Saxena Nishant C | buy | 2026-08-11 | 25036.44 |
| Cohen Yuval | sell | 2026-08-07 | 171395.7 |
| Moran Sean F. | sell | 2026-08-07 | 120970.8 |
| Smethurst Dominic | sell | 2026-03-02 | 50601.44 |
| Cohen Yuval | sell | 2026-02-13 | 107952.44 |
| Moran Sean F. | sell | 2026-02-13 | 36587.88 |
| Hodgson Ian | sell | 2026-02-17 | 6253.4 |
| Smethurst Dominic | sell | 2026-02-03 | 26574.99 |